Key result
In patients with anticoagulant-related intracerebral hemorrhage, 30-day mortality was 53.6%, and intraventricular extension and hemorrhage volume independently predicted case fatality.
Why the study?
Does the choice of reversal agent (vitamin K, plasma, or coagulation factor concentrate) improve survival in patients with anticoagulant-related intracerebral hemorrhage?
Population
151 patients with oral anticoagulant-related intracerebral hemorrhage (ICH) treated at 10 Swedish hospitals
Comparison
Intravenous administration of vitamin K, plasma… vs Withdrawal of anticoagulant treatment only, or…
Design
Cohort
Follow-up
mean 3.5 years
Authors
Loading...
Mortality remains high in anticoagulant-related ICH irrespective of reversal strategy; leaves open optimal agent selection pending randomized data.
Cohort (n=151)
Yes
Does the choice of reversal agent (vitamin K, plasma, or coagulation factor concentrate) improve survival in patients with anticoagulant-related intracerebral hemorrhage?
In patients with anticoagulant-related intracerebral hemorrhage, mortality is high and driven by ICH volume and intraventricular extension, with no clear superiority of any specific reversal agent observed in this retrospective cohort.
Sjöblom et al. (2001) conducted a cohort in Anticoagulant-related intracerebral hemorrhage (n=151). Anticoagulant reversal therapies (plasma, vitamin K, coagulation factor concentrate) vs. Withdrawal of anticoagulant treatment only was evaluated on Case fatality at 30 days and 6 months. In patients with anticoagulant-related intracerebral hemorrhage, 30-day mortality was 53.6%, and intraventricular extension and hemorrhage volume independently predicted case fatality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: